

Testing for *NPM1* mutations in AML

***NPM1*m occurs in 30% of adult cases of AML¹**



AML is a complex, multi-driver disease

- *NPM1*m is a primary driver of AML¹
- *NPM1* mutations remain stable at a rate of ~90% throughout the disease course²⁻⁴



NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) recommendation⁵

- Expedited testing for *NPM1*m at diagnosis and for repeat testing at relapse or progression to guide treatment



Available options for mutational status testing include:

- NGS: a full mutational profile of all clinically relevant biomarkers, including *NPM1*⁵
- PCR: results typically returned within 3-5 days⁶

An FDA-approved test for the detection of *NPM1* mutations is not currently available

See next page for labs with an
NPM1 test turnaround of ≤5 days



Labs with *NPM1* test turnaround of ≤5 days^a

Lab name	Lab contact information	Lab address	Website
BioReference	800-229-5227	491-B Edward H. Ross Drive, Elmwood Park, NJ 07407	bioreference.com
CellNetix	844-344-4209	12501 East Marginal Way S, Suite 200, Tukwila, WA 98168	cellnetix.com
Columbia University Department of Pathology and Cell Biology	212-305-9706	630 West 168th Street, P&S 11th Floor, Room 453, New York, NY 10032	pathology.columbia.edu
Fred Hutch Cancer Center	206-667-2592	Molecular Oncology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Rm D2-281, Seattle, WA 98109	fredhutch.org
GenPath	800-627-1479	481 Edward H. Ross Drive, Elmwood Park, NJ 07407-0621	genpathdiagnostics.com
GoPath Diagnostics	855-467-2849	1000 Corporate Grove Drive, Buffalo Grove, IL 60089	gopathdx.com
Hematologics	206-223-2700	3160 Elliott Avenue, Suite 200, Seattle, WA 98121	hematologics.com
Invivoscribe	866-623-8105	10222 Barnes Canyon Road, Bldg 1, San Diego, CA 92121	invivoscribe.com
UW Medicine	206-606-7060	UW Hematopathology Laboratory, G7-800, Fred Hutchinson Cancer Center, 825 Eastlake Avenue E, Seattle, WA 98109	menu.labmed.washington.edu
Weill Cornell Medicine	212-746-2442	525 East 68th Street, Room Starr 715, New York, NY 10065	pathology.weill.cornell.edu

^aThe resource provided was confirmed by reviewing facility websites and/or contacting facilities directly. Kura Oncology, Inc., and Kyowa Kirin Co., Ltd., do not recommend or endorse any facility or lab on the list. It is the sole responsibility of the healthcare professional to select a facility, and this resource is not exhaustive and is only one source of information to assist in that decision. If you would like to suggest a facility be added to the list, please contact Kura Oncology MedInfo at 844-KURAONC.

Summary of 10 labs that include *NPM1* as a listed test as of October 2025.

AML, acute myeloid leukemia; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; *NPM1*-m, mutated nucleophosmin 1; *NPM1*m, nucleophosmin 1 mutation; PCR, polymerase chain reaction; R/R, relapsed or refractory.

References: 1. Falini B et al. *Blood Cancer Discov.* 2024;5(1):8-20. 2. Papadaki C et al. *Br J Haematol.* 2009;144(4):517-523. 3. Krönke J et al. *J Clin Oncol.* 2011;29(19):2709-2716. 4. Suzuki T et al. *Blood.* 2005;106(8):2854-2861. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 20, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 6. Döhner H et al. *Blood.* 2022;140(12):1345-1377.

